|
|
|
| home > ict > Autumn 2019 |
|
|
 PUBLICATIONS |
International Clinical Trials |
|
|
|
|
|
 |
| |
|
|
|
|
Social Media in Orphan Disease Research
The New Imperative
Barbara Zupancic at Worldwide Clinical Trials evaluates the revolution of social media in clinical research and its newfound importance to the recruitment of rare and orphan disease subjects.
|
|
|
|
Spotlight
A Landmark for Life Science Professionals
DIA Europe 2020 will be taking place in Brussels, bringing you expert insights into new trends and innovations in technology and research, with the patient perspective at the forefront of clinical research.
|
|
|
|
Spotlight
The Spirit of Radical Integration
The Avoca Group is dedicated to enhancing the quality of clinical trial processes, mitigating risks, and providing innovative solutions by bringing together industry experts with their Quality Consortium.
|
|
|
|
Clinical Trial Recruitment in Asia Pacific
The Pacific Rim
Dr Tracy Goeken at Linical Accelovance Group examines the benefits of conducting clinical trials in Asia Pacific, utilising its vast patient population and seeking to resolve the challenges of patient recruitment and retention.
|
|
|
|
|
|
Patient Registries in Dementia Trials
Early Detection for Invisible Patients
Professor Clive Ballard at the University of Exeter Medical School and Dr Dawie Wessels at Accelerated Enrollment Solutions discuss how patient registries can improve the detection of ‘invisible’ patients for dementia trials, presenting a new opportunity for prevention.
|
|
|
|
Response Rates in Dementia Research
The Burden of Time
Minimising participant burden is essential to all medical research, and Shani McCoy at Berkshire Healthcare Foundation Trust assesses the factors that contribute to patient burden in dementia studies.
|
|
|
|
New Frontiers in Alzheimer’s Disease Research
The Practical Alternative
The failures of Alzheimer’s disease research have opened up new approaches to achieve an earlier diagnosis and a more effective treatment approach, argues Timothy Earle at TauRx Theraputics.
|
|
|
|
|
Guidance for Rare Disease Research
The Formula for Success
Dr Pavle Vukojevic, Dr Milan Marinkov, and Dr Jovana Vlajkovic- Josic at Pharm-Olam present a formula for success in improving recruitment, the accuracy of data, and streamlining rare disease clinical trials.
|
|
|
|
Q&A: Clinical Trial Management Systems
Software Solutions
In a conversation with ICT, Ricky Lakhani at PHARMASEAL answers questions about the upcoming trends, benefits, and challenges in designing an effective trial management system using cloud-based software.
|
|
|
|
|
Risk-Based Monitoring and Real-World Data
A Decentralised Ecosystem
There is an appetite for change in the capture, integration, and analysis of valuable data from human subjects, and Ian O’Shaughnessy at ICON explores the synergies between risk-based monitoring, decentralised clinical trials, and eSource.
|
|
|
|
Clinical Data Management and Quality
A Paradigm Shift in Data Monitoring
François Torche at CluePoints examines the impact of regulations on data quality and management, addressing the need for more optimised monitoring approaches in clinical data science.
|
|
|
|
Beyond Analytical Dashboards Without Context
Learning to Fish in Data Lakes
For Craig Morgan at Oracle Health Sciences, companies should seek new technology solutions for data monitoring, making effective use of analytical dashboards for powerful insights.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Sartorius Acquires Cell Culture Specialist Xell AG
The life science company Sartorius, through its subgroup Sartorius
Stedim Biotech, acquired cell culture specialist Xell AG headquartered
in Bielefeld, Germany. Xell AG develops, produces, and markets media and
feed supplements for cell cultures, especially for manufacturing viral
vectors that are used in gene therapeutics and vaccines
More info >> |
|
 |
White Papers |
 |
|
The Importance of ADCC in Assessing Clinically Relevant Differences
Sartorius Stedim BioOutsource Ltd
Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
More info >> |
|
|
